---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000144"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T19:45:37.817715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore raises $24.3M via stock sale; Q1 net loss widens to $16.2M, reaffirms FY25 guidance

## Summary
- Sold 5,928,775 shares at $4.10 for gross proceeds of $24.3M to investors including Legion Partners, Greenhaven, Wynnefield, 325 Capital.
- Q1 FY25 revenue $24.7M (flat YoY); net loss $16.2M ($0.53 per share) vs $10.8M loss prior year.
- Adjusted EBITDA $(1.8)M in line with prior year $(2.0)M; FY25 guidance reaffirmed: rev $126.5-130M, Adj EBITDA $19-21M.
- Installed 5-head isolator filler doubling capacity to $300M revenue potential; signed four new customers including Lindy Biosciences.
- Regained Nasdaq compliance; added two sales reps; plans Investor Day in November to detail medium-term targets.

## SEC filing metadata
- accession: 0001005286-24-000144
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000144/0001005286-24-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000144/lndc-20241003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000144
- JSON: https://secwatch.observer/filing/0001005286-24-000144.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.